Cefiderocol
- Generic Name
- Cefiderocol
- Brand Names
- Fetroja, Fetcroja
- Drug Type
- Small Molecule
- Chemical Formula
- C30H34ClN7O10S2
- CAS Number
- 1225208-94-5
- Unique Ingredient Identifier
- SZ34OMG6E8
- Background
Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics. Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into the bacterial cell through iron channels. It represents a significant addition to antibacterial treatment option as it has proven to ...
- Indication
Cefiderocol is indicated for the treatment of complicated urinary tract infections with or without pyelonephritis.
- Associated Conditions
- Complicated Urinary Tract Infection, Nosocomial Pneumonia, Pyelonephritis, Ventilator Associated Bacterial Pneumonia (VABP)
- Associated Therapies
- -
RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI
- Conditions
- Interventions
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- The University of Queensland
- Target Recruit Count
- 513
- Registration Number
- NCT03869437
- Locations
- 🇸🇬
National University Hospital Singapore, Singapore, Singapore
🇦🇺Westmead Hospital, Sydney, New South Wales, Australia
🇦🇺Royal Brisbane and Womens Hospital, Brisbane, Queensland, Australia
Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 7
- Registration Number
- NCT03862040
- Locations
- 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
🇺🇸North Western University, Chicago, Illinois, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections
- Conditions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Shionogi
- Registration Number
- NCT03780140
Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens
- Conditions
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 300
- Registration Number
- NCT03032380
- Locations
- 🇺🇦
Shionogi Research Site, Zaporizhzhya, Ukraine
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
- First Posted Date
- 2016-03-21
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 152
- Registration Number
- NCT02714595
- Locations
- 🇬🇧
Shionogi Research Site, London, England, United Kingdom
A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
- Conditions
- Interventions
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 452
- Registration Number
- NCT02321800
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.